HK Stock Market Move | LENOVO GROUP (00992) rose more than 7% in late trading; AMD's Lisa Su expects Helios rack shipments to ramp up in the fourth quarter.
LENOVO GROUP (00992) rose more than 7% in late trading. As of press time, it was up 6.51% at HK$20.94, with turnover of HK$2.526 billion.
LENOVO GROUP (00992) rose more than 7% in late trading. As of press time, it was up 6.51% at HK$20.94, with turnover of HK$2.526 billion.
On the news front, AMD Chair and CEO Lisa Su said on the third-quarter 2026 earnings call on the 4th that deployments of the Helios rack-scale AI system are expected to increase significantly in the fourth quarter. When discussing delivery progress, she explicitly mentioned that as production ramps up, OEM and ODM partners including LENOVO GROUP, HPE, Dell, and Supermicro will begin delivering the related systems.
Public information shows that LENOVO GROUP is one of the first OEM manufacturers to adopt the Helios platform, and solutions based on the platform are expected to launch in the fourth quarter of 2026. The delivery arrangements disclosed at this AMD earnings call are consistent with the previously announced product timeline.
Related Articles

HK Stock Market Move | FOSUN INTL (00656) closed nearly 5% higher, with several of its subsidiaries posting strong results; Shanghai Fosun Pharmaceutical's non-recurring net profit rose more than 8% in the first three quarters.

J.P. Morgan: FWD (01828) Q3 New Business Value Beats Expectations; Target Price HK$48

Hybio Pharmaceutical (300199.SZ): HY3003 Injection Receives U.S. FDA Clinical Trial Authorization
HK Stock Market Move | FOSUN INTL (00656) closed nearly 5% higher, with several of its subsidiaries posting strong results; Shanghai Fosun Pharmaceutical's non-recurring net profit rose more than 8% in the first three quarters.

J.P. Morgan: FWD (01828) Q3 New Business Value Beats Expectations; Target Price HK$48

Hybio Pharmaceutical (300199.SZ): HY3003 Injection Receives U.S. FDA Clinical Trial Authorization






